According to Avidity Biosciences's latest financial reports the company's current revenue (TTM) is $9.56 M. In 2022 the company made a revenue of $9.22 M a decrease over the years 2021 revenue that were of $9.32 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $9.56 M | 3.64% |
2022 | $9.22 M | -1.09% |
2021 | $9.32 M | 37.41% |
2020 | $6.78 M | 192.67% |
2019 | $2.31 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 611,793.31% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 395,810.52% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $1.24 B | 12,905.61% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | $0.93 B | 9,709.85% | ๐บ๐ธ USA |
Fate Therapeutics
FATE | $63.53 M | 564.57% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | $0.11 B | 1,062.32% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | $0.11 B | 1,079.54% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | $0.39 B | 4,065.31% | ๐บ๐ธ USA |